Business Wire

INVENTIA-LIFE-SCIENCE

4.12.2023 10:01:33 CET | Business Wire | Press release

Share
Inventia Life Science Announces Third Dimension Grant for 3D Cell Culture Research

Inventia Life Science, a leading advanced cell model company, launched the Inventia Third Dimension Grant today. This grant will allow researchers studying fundamental biology or drug development to model and test hypotheses using 3D cell cultures. These advanced models enable scientists to test questions they’d be unable to answer using 2D cell cultures or animal models.

The Inventia Third Dimension Grant recipient will have Inventia’s RASTRUM benchtop device placed in their lab for three months. They’ll also receive all materials needed to generate at least six 96 or 384 well plates of 3D cell models.

RASTRUM is a high-throughput drop-on-demand bioprinter that can deposit cells and matrix components into common tissue culture microplates to form 3D cell cultures. Inventia opened a lab in Dublin last year to foster the use of advanced cell models throughout Europe.

“With 2D cell models or animal models, it’s impossible to conduct certain research that’s critical to the advancement of novel technologies,” says Daniel Vaughn, Inventia’s EU Commercial Director. “We expect the recipient of this grant to make great strides in their research — and to fully realise the opportunities that 3D models present for impactful breakthroughs — during the time they have the RASTRUM in their lab.”

Traditional 2D cell cultures and animal models lack the ability to accurately model human physiological interactions between tumours and their environment. With RASTRUM advanced cell models, scientists are able to design models that more precisely recreate those interactions allowing them to probe deeper into their field of study.

Application information

The Third Dimension Grant Program is open to academic and commercial laboratories not currently using the RASTRUM Platform in Europe. Applications are due before the 29th February 2024, and the recipient will be selected on 8th March 2024. Applicants should complete the submission form using the grant link.

About Inventia Life Science

Inventia is creating some of the most powerful tools for advanced biomedical discovery today. We build printers and formulate bioinks that, together, allow human cells to be printed in 3-dimensional structures and help forward-thinking pioneers in the fields of cancer research, drug discovery and medicine to create human tissue for research and therapy purposes. Our RASTRUM platform creates 3D cell cultures which imitate real human tissue in terms of structure and behaviour across a range of disease states. The physiological complexity of these cell cultures provides an environment in which world-class research and discovery can occur, right in the researcher’s own lab. Inventia Life Science was the vision of Dr. Julio Ribeiro and was founded by him with Dr. Aidan O'Mahony, Dr. Cameron Ferris and Peter Arthur in 2013. It is headquartered in Sydney, Australia.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231205284641/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release

The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release

Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye